ALCAM and breast cancer: We agree with the potential applications of FN1, PLAU and ALCAM as prognostic and/or predictive biomarkers for breast cancer based on their differential expression upon flow stimulation, interactions with other genes involved in EMT and cell adhesion, relapse free survival analyses and overexpression in most subtypes and at most stages of breast cancer when compared to expression in healthy volunteers.